Evidence map›Paper›PMID 41957250›Full record

ArticleNpj viruses2026

Investigation and impact of mammalian adaptation markers on H5N8 high pathogenicity avian influenza polymerase activity.

Maxime Fusade-Boyer, Arthur Kocher, Pierre Bessière, Thomas Figueroa, Charlotte Foret-Lucas, Timothée Vergne, Christophe Chevalier, Mariette F Ducatez, Romain Volmer

Abstract read
In one paragraph

Article in Npj viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Maxime Fusade-Boyer *Univ Toulouse, ENVT, INRAE, IHAP, Toulouse, France. maxime.fusade-boyer@envt.fr.
Arthur Kocher *Univ Toulouse, ENVT, INRAE, IHAP, Toulouse, France.
Pierre BessièreUniv Toulouse, ENVT, INRAE, IHAP, Toulouse, France.
Thomas FigueroaUniv Toulouse, ENVT, INRAE, IHAP, Toulouse, France.
Charlotte Foret-LucasUniv Toulouse, ENVT, INRAE, IHAP, Toulouse, France.
Timothée VergneUniv Toulouse, ENVT, INRAE, IHAP, Toulouse, France.
Christophe ChevalierUMR892 VIM, UVSQ, INRAE, Université Paris-Saclay, Jouy-en-Josas, F78352, France.
Mariette F DucatezUniv Toulouse, ENVT, INRAE, IHAP, Toulouse, France.
Romain VolmerUniv Toulouse, ENVT, INRAE, IHAP, Toulouse, France.

Funding

Agence Nationale de la Recherche ANR-17-CE35-0007
6 · The paper itself

Abstract

Highly pathogenic H5Nx viruses of clade 2.3.4.4b have spread worldwide, causing major economic losses and increased human exposure. Since 2020, multiple mammalian infections have been reported, raising concerns about further adaptation to mammalian hosts. We analyzed influenza A virus sequences from the Influenza Virus Database at the National Center for Biotechnology Information to identify new mammalian adaptation markers in the polymerase complex and nucleoprotein, using recursive partitioning. These markers were grouped into "proteotypes" to assess their co-occurrence and association with host origin. This analysis revealed distinct groups of proteotypes linked to mammalian adaptation, including those seen in historical and pandemic human strains. Identified mutations were introduced alone or in combination into a 2.3.4.4b H5N8 virus to evaluate their impact on polymerase activity in mammalian cells using a minigenome assay. PB1 V336I and PB2 K702R increased polymerase activity in human cells, particularly with PB2 E627K, supporting enhanced surveillance of 2.3.4.4b H5Nx viruses. These findings highlight mutation combinations relevant for enhanced surveillance of 2.3.4.4b H5Nx viruses.

Identifiers

PMID41957250
PMCPMC13066567

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.